DALLAS, Aug. 22, 2013 /PRNewswire-iReach/ -- The CRO market is highly fragmented and comprised of some 1,000 individual companies, most of which are privately owned. These companies vary significantly in size and breadth of services – from a four person bioanalysis research lab in Thailand to companies like Quintiles and Covance which have tens of thousands of employees in over 100 countries across the globe. For this report, GlobalData identified 11 CROs to apply its benchmarking methodology providing a foundation for strategic discussion and analysis. The coverage in this research examines these CROs from a unique company-centric lens – combining financial performance and resources allocation with partnering activity and regional developments to assess a company's overall strategy. This type of coverage is unlike any other analysis available, and delivers a consistent view into the evolution of these companies corporate growth. The report also covered some 30 other privately-held CROs to give the analysis more specificity and granularity.
PharmaLeaders: CRO Benchmark Report – Financial Benchmarking & Competitive Landscape Assessment of Leading CROs (http://www.reportsnreports.com/reports/267582-pharmaleaders-cro-benchmark-report-financial-benchmarking-competitive-landscape-assessment-of-leading-cros.html ) provides analysis of the key drivers and trends shaping the global CRO market including biologics manufacturing, emerging markets and eClinical technologies, A deep dive into the synergies behind partnering and acquisition activity, Discussion of business line and regional segment strategies, Assessments of company financials by revenue, margin, expense and capital structure, Firm utilization, resources management, and efficiency metrics as well as information on Leadership / management changes.
This research says the CRO sector posted strong growth in 2012. The total combined peer group revenue from these leading CRO companies increased 10.2% year-to-year, from $12.4 billion in 2011 to $13.6 billion in 2012. Largely fueling the growth in the CRO sector was Quintiles, which independently contributed approximately $397 million to the $1.2 billion peer group increase. Quintiles' revenue grew by 12.1% year-on-year to $3.7 billion in 2012, considerably larger than its next closest rival, Covance, at $2.1 billion. Quintiles was effective at turning its order backlog into revenue, and garnering new orders in its clinical services business especially in markets abroad, in Europe and Asia. In fact, most of the companies in this report saw positive year-on-year growth rates in 2012, ranging from 4.0% (Covance) to 22.8% (WuXi), with the exception of Charles River, which saw a slight year-on-year revenue decline of 1.1% largely due to unfavorable foreign exchange rates. The sector posted strong growth in 2012, outpacing the 6.8% increase in aggregate corporate revenue the same peer group recorded in 2011.
Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=267582 .
This report will enable you to analyze and track the strategies that these CROs are using to gain share in the increasingly competitive market, understand the underlying financial metrics that differentiate certain companies from the pack in terms of growth and profitability, spending and asset structure, organize your sales and marketing strategy to identify companies with proprietary technologies to maximize opportunities for strategic investment or partnerships and use this information as an independent source for your due diligence and transaction strategy
Key Questions Answered in this report:
- What specific strategies are these CROs employing to gain market share?
- What drivers accounted for the revenue growth for the company over the past year?
- Which trends will affect the CRO marketplace over the next few years?
- What particular services or capabilities are my competitors developing?
- Who are the revenue and growth leaders in each service line and geography?
- What specific business development activities are taking place, in terms of partnerships or M&A?
- How are CROs growing their physical infrastructures and human resources to better serve the needs of their customers?
- What region-specific operations and capabilities are CROs adding to gain share in emerging markets?
Complete report PharmaLeaders: CRO Benchmark Report – Financial Benchmarking & Competitive Landscape Assessment of Leading CROs available at http://www.reportsnreports.com/reports/267582-pharmaleaders-cro-benchmark-report-financial-benchmarking-competitive-landscape-assessment-of-leading-cros.html .
You may also be interested in similar other reports available with us:
PharmaLeaders: Top 10 Pharmaceutical Companies in India Benchmark Report - Competitive Analysis of the Leading Players in 2013 at http://www.reportsnreports.com/reports/267434-pharmaleaders-top-10-pharmaceutical-companies-in-india-benchmark-report-competitive-analysis-of-the-leading-players-in-2013.html .
PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013 at http://www.reportsnreports.com/reports/232728-pharmaleaders-generic-manufacturers-benchmark-report-financial-benchmarking-competitive-analysis-of-the-leading-generic-players-in-2013.html .
ReportsnReports.com ( http://www.reportsnreports.com/ ) is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. Call +1 888 391 5441 with your research requirements. Explore more reports at http://marketreportsstore.com/ .
Media Contact: Priyank Tiwari, ReportsnReports.com, +1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com